Results from drug target MR analyses to investigate the effect of lipid-lowering therapies on BMI, lipoprotein A, and testosterone.

Estimates of effects from genetically proxied inhibition of PCSK9, NPC1L1, and HMGCR on BMI, levels of lipoprotein A, total testosterone, and bioavailable testosterone. Effect estimates were in SD change in the outcome per drug target inhibition effect equivalent to an SD reduction in LDL-c. Results were from analysis using instruments identified from the GLGC data. BMI, body mass index; GLGC, Global Lipids Genetics Consortium; LDL-c, LDL cholesterol; MR, Mendelian randomization; SD, standard deviation.